NEW YORK (GenomeWeb News) – Integrated Genomics today said that it has licensed its Ergo bioinformatics platform to Evonik Industries for use in optimizing production strains and finding new methods for high-yield production of specialty chemicals.
Integrated Genomics said that the Ergo platform is optimized for analysis of microorganisms and integrates biological data from genomics, biochemistry, gene expression studies, genetics, and literature. It contains data on more than 1,500 genomes in various stages of completion, the Chicago-based firm said.
Thomas Haas, director of Evonik's Science-to-Business Center for biotechnology in Marl, Germany, said Evonik expects the Ergo platform to “assist us in developing new production strains for higher and more cost-effective production of biological compounds.”
Financial terms of the license were not disclosed.